Apoptosis Assays Market Size valued at USD 1.4 Billion in 2022. The Apoptosis Assays market industry is projected to grow from USD 1.53 Billion in 2023 to USD 3.24 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.80% during the forecast period (2023 - 2032). Increased emersion of novel radionuclide tracers and increase in innovative assay kits, and increased investment in R&D activities are the prime market drivers enhancing the growth of market.
Source: The Secondary Research, Primary Research, MRFR Database and Analyst Review
Market CAGR for apoptosis assays is being driven by the rising advent of new radionuclide tracers like caspase inhibitors and radiolabeled annexin V, which has improved the efficiency of the real-time monitoring of cellular death. The ongoing research into apoptosis-modulating medications is another factor anticipated to boost the apoptosis assay market globally. The growing demand for high-content clinical research and diagnostics, mainly for cancer, is fueling the market growth. Infectious diseases like autoimmune diseases, cancer and others are increasing.
The apoptosis assays help in giving in-depth insights into the cell death mechanisms, biological drugs and small molecules and the function of the immune system at the molecular level. Controlling and understanding the mechanism included in several steps of apoptosis helps in new drug innovations. The rising demand for caspase activity assays with the Bcl-2 protein family throughout the pharmaceutical companies for cell death detection has fueled the growth of the market. The immense research is carried out is expected to offer significant momentum to the market penetration of these assays, according to the director of Manufacturers of America and pharmaceutical research. The growing application of assay products will be further expected to be beneficial for different pharmaceutical companies. The key market players are implementing the important fact that the multiple points of confirmation of apoptosis help in epidemiological studies, and therefore, the solutions and product lines are offered depending on different principles.
The programmed cell death mechanism had an important role in the start and progression of different chronic conditions. The broad adoption of clinical cytoprotective and cytotoxic agents in order to treat ischemic diseases, neurodegenerative diseases, and cancer represents one of the leading reasons for the growing demand for apoptosis assays for discovering new drugs. The live-cell and real-time assays are attaining traction with multiple other methods in order to monitor apoptotic events over a period of time. Thus, driving the Apoptosis Assays market revenue.
However, the less availability of skilled personnel for the research and development of apoptosis assays. Cells can undergo apoptosis because the cells that die due to the severe injury typically swell and burst and experience necrosis, thus becoming the factor for obstruction in the market growth.
The Apoptosis Assays market segmentation, based on product, includes Kits, Reagents, and Instruments. The kits segment dominated the market, accounting for the largest market revenue and is expected to remain the same throughout the forecast period. A substantial growth in the adoption of apoptosis assays throughout drug design fabrication and manufacturing is anticipated to provide opportunities for product manufacturers. The investment by the key market players in the development of an affordable and innovative assay kits, with a growing preference for apoptosis assay kits among users, is anticipated to fuel the dominance of the segment. Further, the reagents form an integral part of the apoptosis assay protocols, and therefore it is the fastest-growing segment throughout the forecast period.
Figure 1: Apoptosis Assays Market, by Product, 2022 & 2032 (USD Billion)
Source: The Secondary Research, Primary Research, MRFR Database and Analyst Review
The Apoptosis Assays market segmentation, based on technique, includes Flow Cytometry, Fluorescence Microscopy, Spectrophotometer, and Others. The flow cytometry segment dominates the market due to the inclination of researchers toward adopting flow cytometry-based mitochondrial assays. Flow cytometry assists in making a clear distinction between intact mitochondria and permeabilized mitochondria. Flow cytometry is anticipated to dominate the market globally during the forecast period because it is considered to be a premium standard detection method. Further, the fluorescent microscopy segment is expected to witness the fastest growth.
By region, the study gives market insights into the North America, Europe, Asia-Pacific and the Rest of the World. The North American Apoptosis Assays market area dominates the market due to the presence of major market players, the prevalence of chronic diseases like cancer and the availability of the advanced healthcare infrastructure in this region. Further, the US is the largest contributor to the growth of the market owing to the developments related to apoptosis-modulating drugs in the country and the rising geriatric population.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, Japan, India, China, Australia, South Korea, and Brazil.
Figure 2: APOPTOSIS ASSAYS MARKET SHARE BY REGION 2022 (USD Billion)
Source: The Secondary Research, Primary Research, MRFR Database and Analyst Review
The Asia-Pacific Apoptosis Assays Market accounts for the second-largest market share due to the growing prevalence of chronic and infectious diseases, large patient population, rising healthcare expenditure, and growing interest of key market players in this region. Moreover, China’s Apoptosis Assays market held the largest market share, and the Indian Apoptosis Assays market was the rapid-growing market in Asia-Pacific region.
Europe's Apoptosis Assays market is expected to grow at the rapid CAGR from 2023 to 2032. This is due to the rising prevalence of chronic diseases and growing investment in recent technology. Further, the German Apoptosis Assays market held the largest market share, and the UK Apoptosis Assays market was the rapid-growing market in the European region.
Leading market players are investing hugely in research and development in order to expand their product lines, which will help the Apoptosis Assays market grow even more. Market players are also undertaking a variety of strategic activities to spread their footprint, with important market developments inclusive of new product launches, contractual agreements, higher investments, mergers and acquisitions, and collaboration with other organizations. To spread and survive in a more competitive and rising market climate, the Apoptosis Assays industry must offer cost-effective items.
Manufacturing locally to reduce the operational costs is one of the key business tactics utilized by the manufacturers in the Apoptosis Assays industry to benefit the clients and increase the market sector. In recent years, the Apoptosis Assays industry has offered some of the most significant advantages to the medicine. Major players in the Apoptosis Assays market, including GE Healthcare, Merck & Co Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Thermo Fisher Scientific, Danaher Corporation, Sartorius AG, Geno Technology, GeneCopoeia Inc., Promega Corporation, and others, are trying to increase market demand by investing in the research and development operations.
GE Healthcare Technologies Inc, headquartered in Chicago, Illinois, the US, is an American medical device supplier which fabricates, develops, manufactures and sells diagnostic imaging and clinical imaging systems; services and products for drug delivery, cellular technologies, biopharmaceutical manufacturing and range of healthcare IT solutions. The company also offers services like performance solutions services and performance enhancements, computerized data management and remote diagnostic and repair services of the medical equipment produced by the company and others. The company conducts its operations throughout the globe via affiliates and subsidiaries. In 2018, GE Healthcare Life Sciences inaugurated a novel production facility in Pasching, Austria. The newly opened manufacturing site will assist in strengthening the product supply for biopharmaceutical companies in Europe.
Merck & Co Inc, headquartered in New Jersey, the US, is a biopharmaceutical company that emphasizes on invention, development, production and marketing of prescription medicines, vaccines, biologic therapies, and animal health products. It provides prescription products for therapy areas related to cancer, cardiovascular, immune disorders, respiratory, diabetes and infection. The company offers animal health products like poultry products, vaccines, livestock products and aquaculture products. The company supplies medicines to drugs, retailers, wholesalers, hospitals, and government agencies. In 2015, the company acquired Sigma Aldrich Corporation, a supplier in the research and the fine chemicals market, providing organic and inorganic chemicals, reagents and many more. This acquisition strengthened the life science segment of Merck. SAFC Commercial business of Sigma-Aldrich is now a part of the life science segment of Merck.
Key Companies in the Apoptosis Assays market includes
GE Healthcare
Becton, Dickinson and Company
Bio-Rad Laboratories
Danaher Corporation
Sartorius AG
Geno Technology
GeneCopoeia Inc.
Promega Corporation
Apoptosis Assays Industry Developments
March 2022:KaraMD announced the Pure Health Apple Cider Vinegar Gummies, a vegan gummy emphasized to assist ketosis, digestion regulation, weight management, and encourage greater levels of energy.
January 2022:Solace Nutrition, the US-based medical nutrition company, bought the R-Kane Nutritionals' assets for an unknown sum. This asset acquisition enables Solace Nutrition in order to develop synergy between both brands, accelerate the growth, and to establish a position in an adjacent nutrition sector. The R-Kane Nutritionals is a firm established in the US that specializes in high-protein meal replacement products for weight loss.
February 2021:Hydroxycut's new creation, CUT Energy, a delectable clean energy drink, was intoduced. This powerful mix was carefully formulated for the regular energy drink consumers, the exercise enthusiasts, and dieters looking to lose weight.
Kits
Reagents
Instruments
Flow Cytometry
Fluorescence Microscopy
Spectrophotometer
Others
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Australia
Rest of Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 1.4 Billion |
| Market Size 2023 | USD 1.53 Billion |
| Market Size 2032 | USD 3.24 Billion |
| Compound Annual Growth Rate (CAGR) | 9.80% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, The Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product, Technique and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, Japan, India, China, Australia, South Korea, and Brazil |
| Key Companies Profiled | GE Healthcare, Merck & Co Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Thermo Fisher Scientific, Danaher Corporation, Sartorius AG, Geno Technology, GeneCopoeia Inc., Promega Corporation |
| Key Market Opportunities | Increasing adoption of apoptosis assays. |
| Key Market Dynamics | Increased emersion of novel radionuclide tracers and innovative assay kits. |
Apoptosis Assays Market Highlights:
Frequently Asked Questions (FAQ) :
The Apoptosis Assays market size valued at USD 1.4 Billion in 2022.
The market is foreseen to rise at a CAGR of 9.80% during the forecast period, 2023-2032.
North America had the largest share of the market
The key players in market are GE Healthcare, Merck & Co Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Thermo Fisher Scientific, Danaher Corporation, Sartorius AG, Geno Technology, GeneCopoeia Inc., and Promega Corporation.
The kits category dominated the market in the year 2022.
The Flow Cytometry had the largest share in the market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
